HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains $1.5 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains $1.5 price target.